AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02845063 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: ACE genotyping
Description: Subjects will be genotyped for the ACE-I/D gene polymorphism.
Study NCT02845063 — intervention group
Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: ACE genotyping
Description: Subjects will be genotyped for the ACE-I/D gene polymorphism.
Study NCT02071901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eltrombopag olamine
Description: Given PO
Study NCT03801525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ublituximab
Description: * recombinant chimeric anti-CD20 (cluster of differentiation 20) monoclonal antibody~* administered as an IV infusion
Study NCT03703219 — intervention group
Intervention type: OTHER
Intervention: Mothers Touch Program
Description: Combination of diet, massage, body binding methods along with 40 days of rest following the traditional way of delivering
Study NCT00555048 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic hematopoietic stem cell transplantation
Study NCT00555048 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Study NCT01256736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: intravenously at dose of 8mg/kg over 1 hour infusion every 4weeks
Study NCT01256736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DMARDs
Description: DMARDs(chloroquine, hydroxychloroquine, parenteral gold, sulfasalazine, azathioprine, and leflunomide)
Study NCT03746665 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: meningococcal serogroup A conjugate vaccine
Description: Once final eligibility has been confirmed by a study clinician on the day, expectant mothers will be administered a single intramuscular dose of MenAfriVac™.
Study NCT01124188 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Higher-dose venlafaxine
Description: Dosing of venlafaxine will range from 187.5-300 mg/day.
Study NCT01124188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Higher-dose venlafaxine
Description: Dosing of venlafaxine will range from 187.5-300 mg/day.
Study NCT01124188 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive management
Description: Supportive management encourages participants to take the medication and manages any treatment-emergent side effects. Ten sessions will be delivered over the course of 14 weeks.
Study NCT01124188 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem Solving Therapy for Depression and Pain
Description: PST-DP will be delivered over the course of 10 sessions over 14 weeks. Along with teaching the participant 7 steps of problem solving, PST-DP also includes a medication support and management component.
Study NCT02120599 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ready-to-use supplementary food
Study NCT02120599 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: corn-soy blend
Study NCT02120599 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: corn-soy blend
Study NCT02120599 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: iron
Study NCT02120599 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: folic acid
Study NCT02120599 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: UNIMMAP
Study NCT01645098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: 1 mg/kg IV, additional doses of 0.5 mg/kg as needed
Study NCT01645098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: 0.5 mcg/kg/hr IV
Study NCT00479648 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CSL412
Study NCT00479648 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Inactivated trivalent influenza vaccine
Study NCT02048592 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Impact-Nutridrink
Description: IMPACT (immunonutrition) will be given in the first 8 weeks. Afterwards the patients will be returned to their previous nutrition support \|(Nutridrink) for another 8 weeks.
Study NCT02048592 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nutridrink-Impact
Description: In this group of patients - the study starts with period of 8 weeks with no change of previous nutrition support (Nutridrink). After 8 weeks the laboratory results will be examined ant the patients will switch to immunonutrition (Impact) for another 8 weeks. After the laboratory examination including oxidative stress parameters will be evaluated.
Study NCT03818204 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Magnetic Levator Prosthesis (MLP)
Description: Neodymium magnet embedded in a glasses frame and a polymer embedded (PDMS) micro-magnet array fitted externally to the upper lid with IV 3000 securement film. The IV 3000 is FDA approved for extended wear on the skin. Tegaderm, which is essentially the same adhesive, is even FDA approved as an eye covering (we used Tegaderm in early studies but switched to IV 3000 for its superior ease of handling based on packaging technique).
Study NCT03818204 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Levator Prosthesis (MLP)
Description: Neodymium magnet embedded in a glasses frame and a polymer embedded (PDMS) micro-magnet array fitted externally to the upper lid with IV 3000 securement film. The IV 3000 is FDA approved for extended wear on the skin. Tegaderm, which is essentially the same adhesive, is even FDA approved as an eye covering (we used Tegaderm in early studies but switched to IV 3000 for its superior ease of handling based on packaging technique).
Study NCT02561871 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.RSV.FA2
Description: Participants will receive Intramuscular injection of Ad26.RSV.FA2 (5x10\^10 virus particles \[vp\]) on day 1 and 85 in Group 1. Intramuscular injection of Ad26.RSV.FA2 (5x10\^10 virus particles \[vp\]) on day 1 in Group 2.
Study NCT02561871 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad35.RSV.FA2
Description: Participants will receive Intramuscular injection of Ad35.RSV.FA2 (1x10\^11 virus particles \[vp\]) on day 169 in Group 1. Intramuscular injection of Ad35.RSV.FA2 (1x10\^11 virus particles \[vp\]) on day 85 in Group 2.
Study NCT02561871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive Intramuscular injection of Placebo control on day 169 in Group 2. Intramuscular injection of Placebo control on day 1, 85 and 169 in Group 3.
Study NCT03656094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus chemotherapy
Description: Pembrolizumab plus chemotherapy
Study NCT00987623 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: nelfilcon A contact lens
Description: Commercially marketed, hydrogel, single-vision contact lens for daily wear, daily disposable use.
Study NCT00987623 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: narafilcon A contact lens
Description: Commercially marketed, silicone hydrogel, single-vision contact lens for daily wear, daily disposable use.
Study NCT02236949 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pain Practice Change Booster Intervention
Description: See experimental arm for a description of the intervention
Study NCT04593693 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Invia Motion Endure NPWT system
Description: lightweight portable single patient use pump, that provides continous or intermittent operation and multiple negative pressure selection options
Study NCT00488579 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Two policies of iron prophylaxis
Description: 60mg ferrous sulphate daily (+folic acid); Screening and therapy: Hb measurement on each visit, Hb>9g/dl only folic acid, Hb\<9g/dl 60-120 of ferrous sulphate daily (+folic acid).
Study NCT03656094 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo plus chemotherapy
Description: Placebo plus chemotherapy
Study NCT00646841 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxazosin gastrointestinal therapeutic system (GITS)
Description: 4 mg/day, and was titrated, if necessary, to 8 mg/day at Week 3 (Visit 5) or Week 5 (Visit 6).
Study NCT03590522 — intervention group
Intervention type: GENETIC
Intervention: Ryanodine Receptor 2 gene expression
Description: Ryanodine Receptor 2 gene expression will be measured by real time PCR. In addition, amino acids analysis will be measured in plasma by amino acid analyzer.
Study NCT03491553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selgantolimod
Description: Tablet(s) administered orally once weekly
Study NCT03491553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to match (PTM) selgantolimod tablet(s) administered orally once weekly
Study NCT03491553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hepatitis B virus (HBV) OAV Therapy
Description: Commercially available HBV OAV therapy could include one of the following:~Tenofovir disoproxil fumarate (TDF; Viread®) Entecavir (Baraclude®) Adefovir (Hepsera®) Lamivudine (Epivir® ) Telbivudine (Tyzeka®) Tenofovir alafenamide (TAF; Vemlidy®)
Study NCT01180192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxygen
Description: either 8 L/minute O2 via face mask for 2 hours
Study NCT00773708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: raltegravir
Description: intensify their therapy with Raltegravir(RAL):1 Protease inhibitor plus 2 nucleoside reverse transcriptase inhibitor plus RAL or 1 non-nucleoside reverse transcriptase inhibitor plus 2 nucleoside reverse transcriptase inhibitor plus RAL
Study NCT01400776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WC3011 Estradiol Vaginal Cream
Description: WC3011 estradiol vaginal cream administered once daily for 2 weeks followed by 2X/week or 3X/week for 10 weeks, total treatment duration 12 weeks
Study NCT03778723 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rescue fentanyl
Description: Fentanyl in repeated doses (50 µg) when needed (heart rate or mean arterial blood pressure increase more than 20% of the basal value) are used for maintenance of analgesia
Study NCT03778723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rescue fentanyl
Description: Fentanyl in repeated doses (50 µg) when needed (heart rate or mean arterial blood pressure increase more than 20% of the basal value) are used for maintenance of analgesia
Study NCT04684693 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser
Description: Laser puncture and exercise
Study NCT04684693 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Exercise
Study NCT03447886 — intervention group
Intervention type: OTHER
Intervention: Phone interview
Description: Collecting clinical and socio-demographic information.
Study NCT01567826 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard of care lipid therapy
Description: Patients will be randomized in a 1:1 fashion to receive either A) Rosuvastatin (Crestor) 40mg daily, or B) standard-care lipid-lowering therapy.~Zocor, Lipitor \[any dose\] and Crestor \[less than 40mg\]
Study NCT01567826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aggressive lipid therapy
Description: Patients will be randomized in a 1:1 fashion to receive either A) Rosuvastatin (Crestor) 40mg daily, or B) standard-care lipid-lowering therapy.
Study NCT00737737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MS Contin
Study NCT00737737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT02815202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY987517
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Code: Z12-034)
Study NCT00700817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: 1.2 mg once daily, subcutaneous (under the skin) injection
Study NCT05673863 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychological Resilience Program
Description: The psychological resilience program was applied to the children in the intervention group twice a week for a total of 5 weeks. Each session consisted of 90 minutes of structured practice. The application is carried out using narrative therapy, cognitive behavioral therapy, psychodrama and analogy techniques, self-assessment and didactic teaching techniques. In addition, participants were engaged in self-regulation exercises and positive imagery activities. Each session includes practices on empathy, stress management, resilience, realistic and unrealistic thinking, optimism and pessimism, autonomy and humor related to resilience.
Study NCT03506399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanabecestat
Description: Administered orally
Study NCT01400776 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle administered once daily for 2 weeks followed by 2X/week or 3X/week for 10 weeks, total treatment duration 12 weeks.
Study NCT01951508 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Methylphenidate
Description: 60mg per os, single dose
Study NCT01951508 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Modafinil
Description: 600mg per os, single dose
Study NCT01951508 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: MDMA
Description: 125mg per os, single dose
Study NCT01951508 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: per os
Study NCT01755897 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radical hysterectomy + pelvic lymph node dissection
Study NCT01755897 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: radical hysterectomy + pelvic lymph node dissection
Study NCT01755897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 135-175 mg/m(2) intravenously (IV) on day 1
Study NCT01755897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 75 mg/m(2) IV on day 2 and 3
Study NCT01755897 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: 35 mg/m(2) IV once a week
Study NCT01755897 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic RT
Description: IMRT
Study NCT03698396 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogenic Islet Cell Transplantation
Description: Transplantation of allogenic islet cells will be given to eligible patients, up to three times during the study, using cell quantities based on body weight.
Study NCT00309595 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: stent
Description: Cordis SMART™ Nitinol Stent System
Study NCT00309595 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: balloon
Description: balloon angioplasty
Study NCT01284907 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3 (Cholecalciferol)
Description: Vit D3 ( Cholecalciferol) 1200 IU oral daily for 6 months
Study NCT01284907 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Drops
Study NCT00700817 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sitagliptin
Description: Tablets, 100 mg daily
Study NCT00700817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sitagliptin
Description: Tablets, 100 mg daily
Study NCT00700817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: Tablets, minimum 1500 mg daily
Study NCT03506399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Contraceptive
Description: Administered orally
Study NCT04442919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor followed with Methoxyflurane
Description: patients who received ticagrelor followed with inhaled methoxyflurane due to unstable angina
Study NCT04442919 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor followed with Morphine
Description: patients who received ticagrelor followed with intravenous morphine due to unstable angina
Study NCT03158025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lemborexant tablets
Description: Lemborexant 1 x 10 mg, 2 x 10 mg, or 3 x 10 mg tablets will be administered orally.
Study NCT04442919 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor alone
Description: patients who received ticagrelor without any analgesia due to unstable angina
Study NCT00534937 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Compression wrapping
Description: Short-stretch compression wrap will be applied at least once a week.
Study NCT00534937 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Flexitouch compression pump
Description: In addition to short-stretch wrapping, this group will received once-daily Flexitouch compression pump, both at home and during the once-a-week clinic visits.
Study NCT00787033 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04554878
Description: Oral pills at increasing dose twice daily, 21 day cycle, continuous treatment schedule until progression of disease, unacceptable toxicity, or patient request. Some patients will undergo serial biopsy and/or FDG-PET imaging
Study NCT02937831 — intervention group
Intervention type: BIOLOGICAL
Intervention: RIXUBIS
Study NCT01446068 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High-fat meal
Description: Three caloric doses of high-fat meal (500, 1000, 1500 kcal)
Study NCT01959126 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress-reduction class
Description: Study participants enrolled in a 12-week stress reduction course based on the principles of mindfulness. They attended four six-hour workshops and participated in 12 weekly hour-long web video conferencing calls to reinforce what was taught in the workshops. We have two groups: chronically-stressed maternal caregivers of children on the autism spectrum and control mothers whose children have no significant psychiatric or physical impairment. Both groups received similar instruction.
Study NCT00812877 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mineral Trioxide Aggregate
Description: Pulp capping agent, Mineral TrioxideAggregate
Study NCT00812877 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium Hydroxide
Description: Pulp capping agent, Calcium Hydroxide
Study NCT02329457 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Zostavax
Description: varicella zoster vaccine
Study NCT02329457 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Zostavax
Description: varicella zoster vaccine
Study NCT02329457 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: normal saline placebo vaccine
Study NCT03720210 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RFA
Description: Radiofrequency ablation of a portion of thyroid parenchyma to treat amiodarone-induced thyrotoxicosis
Study NCT00703911 — intervention group
Intervention type: DRUG
Intervention: eptacog alfa (activated)
Description: Treatment of patients experiencing bleeds at the discretion of the physician/caregiver
Study NCT04529382 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cognitive testing (Bayley III, WPPSI III and WISC V)
Description: Parents and children will be invited to come for an outpatient clinic visit where cognitive testing and neurologic examination will be performed. In addition to this parents will be asked to fill in questionnaires, provide latest school results and medical files will be requested from treating physicians.
Study NCT02817334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: indocyanine green
Description: As inject only indocyanine green (ICG), it provide the surgeon visual guidance to ensure better outcome.
Study NCT01908296 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FK949E
Description: Oral
Study NCT01908296 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluvoxamine
Description: Oral
Study NCT03607708 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy (MBCT)
Description: The MBCT intervention will consist of group conducted meditative practices, lasting 2 hours per week for 8 weeks. Patients will be invited to try various techniques during sessions (brief silent meditations, guided meditations, body scans, gentle arm movement exercises).
Study NCT03607708 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health Enhancement Program (HEP)
Description: Health Enhancement Program (HEP) : Has been previously designed and used for the purpose of being a manualized active control in meditation-based intervention trials, controlling for several non-specific factors found in a mindfulness meditation group. Participants will learn about health promotion, healthy diet, music, exercise as well as implementing positive health-enhancing life changes both in-session and during at-home practice with the support of a group facilitator, but do not learn mindfulness techniques.